Keyphrases
Aberrations
8%
ABL1
5%
Acute Lymphoblastic Leukemia
73%
Acute Lymphoblastic Leukemia Cells
9%
Antibody-dependent Cellular Phagocytosis
9%
Ara-C
9%
AUTS2
9%
B Cell Development
5%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
25%
B-cell Precursors
10%
BCP-ALL
63%
BCR-ABL1
11%
Blood Cancer
5%
Bone Marrow
6%
Bosutinib
5%
Bother
5%
CD22
7%
Cell Tumor
5%
Central Nervous System Involvement
9%
Childhood Acute Lymphoblastic Leukemia
20%
Childhood B-ALL
9%
Children with Cancer
5%
Chromosomal Instability
5%
Clinical Outcomes
5%
Clinical Trials
6%
Common Region
9%
Confidence Interval
10%
Copy number
10%
Copy number Variation
10%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
8%
Cytarabine
9%
Dose-limiting Toxicity
7%
Down Syndrome
8%
Drug Resistance
5%
Dutch
8%
DUX4
5%
ETV6-RUNX1
24%
Event-free Survival
17%
Extramedullary
5%
Fusion Gene
5%
Gemtuzumab Ozogamicin
9%
Genetic Subtypes
10%
Germ Cells
5%
Hematopoietic Stem Cell Transplantation
8%
High Hyperdiploidy
5%
High Risk
10%
Hyperdiploid
20%
Hyperdiploidy
5%
IKZF1
23%
IKZF1 Deletion
21%
IKZF1 Gene Deletion
9%
Improved Outcomes
6%
Intrachromosomal Amplification of Chromosome 21 (iAMP21)
14%
Janus Kinase 2 (JAK2)
5%
Kinase Domain mutations
9%
Leukemia
13%
Leukemia Patients
18%
Leukemic Cells
8%
Lymphoblastic Lymphoma
9%
Lymphoblastic Malignancies
5%
Media Risk
9%
Mesenchymal Stromal Cells
5%
Minimal Residual Disease
42%
Mutational Landscape
9%
Newly Diagnosed
7%
Overall Response Rate
5%
Overall Survival
11%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
12%
PAX5
15%
Pediatric
36%
Pediatric Acute Lymphoblastic Leukemia
11%
Pediatric Cancer
6%
Pediatric Patients
17%
Phase II Trial
5%
Poor Outcome
13%
Primary B Cells
5%
Prognostic Effect
9%
Relapse Risk
5%
Relapsed or Refractory
12%
Risk Score
5%
Risk Stratification
6%
RNA Sequencing (RNA-seq)
7%
Signal Transduction Inhibitors
6%
Standard Risk
5%
Targeted Therapy
10%
TCF3-PBX1
5%
Therapeutic Target
5%
Transcriptional Landscape
9%
Treatment Protocol
6%
Tyrosine Kinase Inhibitor
12%
Tyrosine Kinase Inhibitor Resistance
9%
Whole Exome Sequencing
6%
Working Diagnosis
6%
Biochemistry, Genetics and Molecular Biology
Adolescence
7%
B Cell
100%
Cell Maturation
5%
Cell Viability
5%
Chromosome 21
20%
Chromosome Instability
5%
Clinical Trial
8%
Cytarabine
9%
Cytogenetics
6%
Down Syndrome
14%
Drug Resistance
5%
DUX4
5%
Enhancer Region
5%
ETV6
25%
Event Free Survival
11%
Exome Sequencing
5%
Gene Deletion
9%
Genetics
15%
Germ Cell
10%
Germline
10%
High Risk Population
13%
IKZF1
37%
Imatinib
6%
Janus Kinase
5%
Kinase
14%
Overall Survival
11%
PAX5
13%
Phosphotransferase
14%
Precursor
85%
RNA Sequence
17%
RUNX1
25%
SH3 Domain
9%
T Cell
6%
Targeted Therapy
6%
Tyrosine Kinase Inhibitor
14%
Medicine and Dentistry
Acute B-Cell Lymphoblastic Leukemia
13%
Acute Lymphoblastic Leukemia
96%
Acute Lymphocytic Leukemia
6%
Adolescence
6%
B Cell
42%
Cancer
5%
Clinical Trial
5%
Event Free Survival
9%
Germ Cell
8%
Hematological Cancer
5%
Hematopoietic Stem Cell Transplantation
8%
High Risk Population
6%
Inotuzumab Ozogamicin
9%
Janus Kinase
5%
Leukemia
9%
Leukemia Cell
8%
Leukemia in Children
10%
Malignant Neoplasm
10%
Minimal Residual Disease
35%
Neoplasm
11%
Overall Survival
9%
Pediatric Cancer
5%
Pediatrics
32%
Pediatrics Patient
12%
Personalized Medicine
7%
Precursor
35%
Prognostic Factor
6%
Risk Stratification
9%
Targeted Therapy
5%
Tyrosine-Kinase Inhibitor
9%